Back

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

Abstract number: 1134_02_275

Falagas M., Rizos M., Bliziotis I., Rellos K., Kasiakou S., Michalopoulos A.

Objective:

To study the toxicity of prolonged intravenous administration of colistin

Design:

Observational study of retrospective cohort.

Setting:

‘Henry Dunant’ Hospital, a 450-bed tertiary care centre in Athens, Greece.

Participants:

Patients who received intravenous colistin for more than 4 weeks for the treatment of multidrug resistant Gram-negative infections.

Main outcome measures:

Serum creatinine, blood urea, liver function tests, symptoms and signs of neurotoxicity.

Results:

We present our experience with the use of 19 courses of prolonged intravenous colistin [mean duration of administration (±SD) 43.4 (±14.6) days, mean daily dosage (±SD) 4.4 (±2.1) million IU, mean cumulative dosage (±SD) 190.4 (±91.0) million IU] in 17 patients. The median creatinine value increased by 0.25 mg/dl during the treatment compared to the baseline (p < 0.001) but returned close to the baseline at the end of treatment (higher by 0.1 mg/dl, p = 0.67). No apnea or other evidence of neuromuscular blockade was noted in any of these patients who received prolonged treatment with colistin.

Conclusions:

No serious toxicity was observed in patients who received prolonged intravenous colistin. Colistin should be considered as a therapeutic option in patients with infections due to multidrug resistant Gram-negative bacteria.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Subject:
Location: Oxford, UK
Presentation type:
Back to top